Please login to the form below

Not currently logged in
Email:
Password:

lubiprostone

This page shows the latest lubiprostone news and features for those working in and with pharma, biotech and healthcare.

Mallinckrodt pays $1.2bn for Sucampo Pharma

Mallinckrodt pays $1.2bn for Sucampo Pharma

Mallinckrodt is paying $18 per share for Sucampo and will also assume the company’s $360m debt under the terms of the deal, adding Amitizia (lubiprostone), glaucoma treatment Rescula (unoprostone isopropyl)

Latest news

  • Lilly’s Efient and Sucampo's Amitiza win NICE backing Lilly’s Efient and Sucampo's Amitiza win NICE backing

    NICE, which provides healthcare recommendations to the NHS, issued new guidance on the use of Sucampo Pharma Europe's Amitiza (lubiprostone) for adults with chronic idiopathic constipation and updated its view

  • NICE backs constipation treatment NICE backs constipation treatment

    Sucampo’s Amitiza set for NHS use in England and Wales.  . Sucampo's constipation treatment Amitiza (lubiprostone) should be available on the NHS, according to new healthcare guidance. ... For many of the patients who are refractory to standard

  • AZ drug for opioid constipation starts FDA review AZ drug for opioid constipation starts FDA review

    up to compete with Sucampo and Takeda's twice-daily Amitiza (lubiprostone).

  • An unexpected turn

    Lubiprostone. Amitiza (Takeda Pharmaceuticals). Irritable Bowel Syndrome. US. Mycophenolate mofetil (Cellcept; Roche) is an immunosupressant commonly used for treating and preventing transplant rejection.

  • IBS drug approved in the US

    The drug (lubiprostone), which was developed as part of a joint deal between Sucampo and Takeda Pharmaceuticals North America, can now be prescribed to women over the age of 18 for

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics